Telomerase is frequently activated in tumors with microsatellite instability

Cancer Biology and Therapy

Volumn 3, Issue 3, 2004, Pages 289-292

  Ibanez De Caceres, Inmaculada ^a   Frolova, Natalya ^a   Varkonyi, Robert J ^a   Dulaimi, Essel ^a   Meropol, Neal J ^a   Broccoli, Dominique ^a   Cairns, Paul ^a,b  

^a Department of Surgical Oncology ^*  (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Microsatellite instability; Mismatch repair; Telomerase

Indexed keywords

TELOMERASE; MICROSATELLITE DNA;

ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; ENDOMETRIUM TUMOR; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN CELL; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; OVARY CARCINOMA; TELOMERE; TRANSITIONAL CELL CARCINOMA; TUMOR; BASE MISPAIRING; COLORECTAL TUMOR; DNA DAMAGE; DNA REPAIR; FEMALE; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; OVARY TUMOR;

BASE PAIR MISMATCH; CARCINOMA, TRANSITIONAL CELL; COLORECTAL NEOPLASMS; DNA DAMAGE; DNA MUTATIONAL ANALYSIS; DNA REPAIR; FEMALE; HUMANS; MICROSATELLITE REPEATS; OVARIAN NEOPLASMS; TELOMERASE; TELOMERE;

EID: 16544383400     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.3.695     Document Type: Article

References (28)

1. Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 1998; 8:279-82.
2. Bodnar AG, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279:349-52.
3. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33:787-91.
4. Counter CM, Hirte HW, Bacchetti S, Harley C. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA 1994; 91:2900-04.
5. Kim NW, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266:2011-15.
6. Damm K, et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 2001; 20:6958-68.
7. Zhang X, Mar V, Zhou W, Harrington L, Robinson M. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 1999; 13:2388-99.
8. Hahn W, et al. Inhibition of telomerase limits the growth of human cancer cells. Nature Medicine 1999; 5:1164-70.
9. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995; 14:4240-48.
10. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997; 3:1271-4.
11. Cerone MA, Londono-Vallejo JA, Bacchetti S. Telomere maintenance by telomerase and by recombination can coexist in human cells. Hum Mol Genet 2001; 10:1945-52.
12. Grobelny JV, Kulp-McEliece M, Broccoli D. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening to telomeres (ALT) pathway. Hum Mol Genet 2001; 10:1953-61.
13. Perrem K, Colgin LM, Neumann AA, Yeager TR, Reddel RR. Coexistence of alternative lengthening of Telomeres and Telomerase in hTERT-transfected GM847 cells. Mol Cell Biol 2001; 12:3862-75.
14. Lundblad V, Blackburn EH. An alternative pathway for yeast telomere maintenance rescues est1- senescence. Cell 1993; 73:347-60.
15. Chen Q, Ijpma A, Greider CW. Two survivor pathways that allow growth in the absence of telomerase are generated by distinct telomere recombination events. Mol Cell Biol 2001; 21:1819-27.
16. Le S, Moore JK, Haber JE, Greider CW. RAD50 and RAD51 define two pathways that collaborate to maintain telomeres in the absence of telomerase. Genetics 1999; 152:143-52.
17. Teng SC, Zakian VA. Telomeretelomere recombination is an efficient bypass pathway for telomere maintenance in Saccharomyces cerevisiae. Mol Cell Biol 1999; 19:8083-93.
18. Yeager T, et al. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 1999; 59:4175-9.
19. Dunham MA, Neymann AA, Fasching CL, Reddel RR. Telomere maintenance by recombination in human cells. Nature Genetics 2000; 26:447-50.
20. Boland CR. Hereditary nonpolyposis colorectal cancer (HNPCC) In: Vogelstein B, Kinzler KW, eds. New York: McGraw-Hill, 2002.
21. Kane MF, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997; 57:808-11.
22. Boland CR, et al. A National cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of micro satellite instability in colorectal cancer. Cancer Res 1998; 58:5248-57.
23. Rizki A, Lundblad V. Defects in mismatch repair promote telomerase-independent proliferation. Nature 2001; 411:713-6.
24. Broccoli D, Godley LA, Donehower LA, Varmus HE, de Lange T. Telomerase activation in mouse mammary tumors: Lack of telomere shortening and evidence for regulation of telomerase with RNA cell proliferation. Mol Cell Biol 1996; 16:3765-72.
25. Herbert BS, Pongracz K, Shay JW, Gryaznov SM, Shea-Herbert B. Oligonucleotide N3′->P5′ phosphoramidates as efficient telomerase inhibitors. Oncogene 2002; 21:638-42.
26. Cairns P, Tokino K, Eby Y, Sidransky D. Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res 1994; 54:1422-4.
27. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA 1995; 92:9082-6.
28. McElligott R, Wellinger RJ. The terminal structure of mammalian chromosomes. EMBO J 1997; 16:3705-14.